arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Viatris Inc

VTRS
$16.41 ▲ +0.14 (+0.86%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
30 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

Viatris Inc faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $19.0B
Dividend Yield 0.73%
Revenue Growth 8.1%
Op. Margin -2.3%
ROIC 0.5%
FCF / Share $0.30
Trailing P/E 109.4x
Price / Book
FCF Yield 1.8%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.52B
↑ +8.1%
Net Income Profit after all expenses
$176.40M
↑ +237.6%
Operating Margin Operating profit as % of sales
-2.3%
↑ +56.4% 11th
FCF / Share Free cash flow per share
$0.30
↓ -27.1%
Long-Term Debt Long-term obligations
$12.41B
↓ -0.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
30
Financial Health
35
Cash Quality
13

Dividend History

Dividend / share · sourced from SEC filings
$0.48 Latest / share
+0.0% YoY
+34.3% 6-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters